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nKillip class 1
Killip class
2
Killip class
3
Killip class
4
n3821 n281 n94 n146
Patients
Age (years) 61.7 13 70.0 13.2 69.1 12.4 69.5 13.1
Male 2995 (78.4%) 188 (66.9%) 70 (74.5%) 96 (65.8%)
Hypertension 1448 (38.0%) 148 (53.2%) 51 (54.3%) 75 (53.2%)
Diabetes 391 (10.5%) 45 (16.5%) 19 (20.2%) 25 (17.1%)
Current smoker 1469 (38.7%) 60 (21.7%) 29 (31.2%) 34 (23.3%)
Prior myocardial
infarction
260 (6.8%) 26 (9.3%) 14 (15.0%) 14 (9.6%)
STEMI
Anterior area 1576 (41.3%) 171 (61.1%) 54 (58.7%) 65 (44.8%)
Mean delay*
(minutes)
175 150 210 180 220 144 154 137
Thrombolysis
prior to
admission
638 (16.7%) 36 (12.8%) 10 (10.6%) 12 (8.2%)
Coronary
angioplasty
2734 (71.6%) 200 (71.2%) 68 (72.3%) 107 (73.3%)
3-vessels or left
main coronary
artery disease
621 (16.7%) 65 (24.3%) 32 (36.0%) 53 (41.4%)
Haemodynamic
at admission
Heart rate
(/min)
75.2 17 80.7 19 91.6 22 82.7 35
Systolic arterial
pressure
(mmHg)
133.8 25 127.8 27 122.1 29 88.3 28
Need for a
circulatory
assistance**
75 (1.9%) 21 (7.4%) 12 (12.7%) 61 (41.8%)
*“Mean delay” is mean delay between onset of symptoms and admission in the
interventional cardiology centre.
**“circulatory assistance is intra aortic balloon pump and/or extracorporeal life
support.
Conclusions: Killip classification is still relevant for prediction of intra hospital outcome,
notably intra hospital mortality.
TCT-465
Prevalence, Correlation and Clinical Outcome of Intra-procedural Stent
Thrombosis in Patients Undergoing Primary Percutaneous Coronary
Intervention for Acute Coronary Syndrome
Yingjia Xu1, Xinkai Qu1, Xingbiao Qiu1, Hui Chen1, Shaofeng Guan1,
Jingjie Dai1, Weiyi Fang1
1Shanghai Chest Hospital, Shanghai, China
Background: The occurrence, correlation and clinical outcome of intra-procedural stent
thrombosis (IPST) in patients undergoing primary percutaneous coronary intervention
(PCI) in the setting of acute coronary syndromes (ACS) have not been previously
described.
Methods: This retrospective study comprised a review of 1901 consecutive ACS patients
who received primary PCI in our center during the period of January 2006 to January
2011. IPST was defined as new, reappearing or increased (compared to baseline)
thrombus within the deployed stent before the index PCI procedure was completed. All
angiograms were independently reviewed frame-by-frame for the incidence of IPST.
Patient demographics, coronary risk factors, follow-up visits, and all relevant information
were retrieved from the hospital database. Patients with and without IPST were compared
with respect to clinical characteristics, angiographic parameters and cardiac events at
1-year follow-up.
Results: Overall, there were 23 cases of IPST detected in the study cohort, thus, the
prevalence of IPST was 1.2% in this group. There were no significant differences in terms
of baseline clinical characteristics between the two groups. Patients with compared to
those without IPST had significantly more bifurcation lesions involved, and more
thrombus burden at baseline. IPST group compared to no IPST group had 100% more
major adverse events on 1-year follow-up (30.4% vs. 14.4%, P0.02).
Conclusions: IPST was a rare complication of PCI in the setting of ACS. It correlated
with a few procedural factors and was more likely to cause cardiac events during 1-year
follow-up.
Table. Clinical characteristics, angiographic parameters, and clinical event
rates comparing patients with vs. without IPST
Variable IPST (N23)
No IPST
(N1878) p value
Age 61.1 [53.2, 69.1] 60.5 [52.1, 70.0] 0.91
% Diabetes Mellitus (%) 21.7 (5/23) 20.2 (380/1878) 0.86
% Previous MI (%) 17.4 (4/23) 21.6 (405/1878) 0.63
% Previous PCI (%) 17.4 (4/23) 19.2 (361/1878) 0.82
Minimum Pre-PCI TIMI Flow 0.00 [0.00, 1.00] 2.00 [0.00, 3.00] .0001
# of Attempted Vessels 1.00 [1.00, 1.00] 1.00 [1.00, 1.00] 0.10
1 year composite MACE, % 30.4% (7) 14.4% (270) 0.02
IPST, intraprocedural stent thrombosis; MI, myocardial infarction; PCI,
percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction;
MACE, major adverse cardiac events
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Background: Primary angioplasty is the best reperfusion strategy in ST elevation
myocardial infarction (STEMI). Thrombus aspiration with different devices might add a
clinical benefit following the results of the TAPAS study although findings from the
recent INFUSE-AMI trial questions this statement. We sought to analyze the clinical
impact of the use of aspiration devices.
Methods: From a retrospective multicenter (16 hospitals) study that compared different
drug-eluting stents in the STEMI setting we have analyzed the clinical impact of the use
of thrombectomy. Patients were consecutively included. Demographic and clinical data
were collected and a systematic follow up was performed.
Results: A total of 734 patients were included. A thrombectomy device was used in 211
patients (29%). After two years follow up the survival free from death and myocardial
infarction (MI) was 95% in the group with thrombectomy vs. 87.2% in the group without
(p0.001) and the survival free from death, MI and TLR was 93% and 84.6%
respectively (p0.002). Definite plus probable thrombosis incidence was 1% in the group
with thrombectomy and 3.2% in the group without (p0.09). Thrombectomy turned out
to be an independent predictor of death and MI (HR 0.2 IC 95% 0.08-0.6; p0.002) as
well as an independent predictor of the combined end point of death, MI and TLR (HR
0.4 IC 95% 0.2-0.8: p0.02) in a Cox regression analysis. This benefit was independent
of the type of stent used.
Conclusions: The results of this multicenter retrospective registry show that the use of
thrombus aspiration devices in the primary angioplasty with DES was associated to better
clinical outcomes.
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